

Policy Statement; The prescribing of perindopril arginine/Coversyl Arginine and Coversyl Arginine Plus is not supported

Mid Essex Clinical Commissioning Group does not support the prescribing of perindopril arginine or perindopril arginine/indapamide combination product and generic perindopril erbumine is the preferred choice.

Recommendations:

- Do not prescribe perindopril arginine/Coversyl Arginine and Coversyl Arginine Plus in any new patients.
- Existing patients should have perindopril arginine/Coversyl Arginine and Coversyl Arginine Plus reviewed for switching to generic perindopril erbumine.

Rationale:

- Perindopril is available as different salts, perindopril arginine (Coversyl Arginine) and perindopril erbumine. Perindopril arginine has no clinical benefit over generic perindopril erbumine and no difference in safety profile, but is more costly.
- Patients currently prescribed perindopril arginine or perindopril arginine/indapamide should be reviewed and assessed
- The potential switch options from perindopril arginine (Coversyl Arginine) to perindopril erbumine are shown in the table below (recommended dose equivalence):

Current treatment	Switch to
Coversyl Arginine (perindopril arginine) 2.5mg once daily	Perindopril erbumine 2mg once daily
Coversyl Arginine (perindopril arginine) 5mg once daily	Perindopril erbumine 4mg once daily
Coversyl Arginine (perindopril arginine) 10mg once daily	Perindopril erbumine 8mg once daily

Perindopril arginine/indapamide combination product (Coversyl Arginine Plus) contains perindopril arginine 5mg and indapamide 1.25mg. There is no direct switch from perindopril arginine/indapamide, however, prescribing perindopril erbumine 4mg plus an appropriate diuretic as a separate component is the best option. This provides greater flexibility of dosing. An appropriate diuretic would be indapamide (1.5mg modified release once daily or 2.5mg once daily) according to the NICE clinical guideline for hypertension, with appropriate monitoring.

Providers commissioned to provide services on behalf of Mid-Essex CCG are reminded that they are required to follow the Mid-Essex CCG formulary and prescribing guidance as detailed in the Medicines Management Service Specification.

See Mid-Essex CCG website – Medicines optimisation page for all prescribing guidance:

<http://midessexccg.nhs.uk/your-health-services/medicines-optimisation>

Title	Perindopril arginine policy statement
Document reference	PerindoprilArgininePOL201708V1.0FINAL
Author	Medicines Optimisation Team MECCG
Reference:	PrescQIPP bulletin 62, February 2014 https://www.prescgipp.info/-tramacet/send/59-tramacet/946-bulletin-62-tramacet
Approved by	Medicines Management Committee
Date approved	August 2017
Next review date	August 2022

Previous version	Key Changes
N/A	New policy